Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Claris Biotherapeutics has secured $118 million in a Series B funding round led by Samsara BioCapital and Catalio Capital Management to develop its experimental eye drug.
PRIVATEJul 28, 2026•2 days ago
Amount Raised
$118 Million
Round Type
Series B
Jersey CityBiotechnology
Investors
Novo HoldingsSofinnova InvestmentsCatalio Capital ManagementSamsara Bio Capital
Description
Claris Biotherapeutics has netted $118 million to support its bid to develop an experimental eye drug targeting limbal stem cell deficiency. The round was co-led by Samsara BioCapital and Catalio Capital Management, alongside other investors like Sofinnova Investments and Novo Holdings. The funds will aid Claris in propelling its prospect into late-stage testing early next year. The newly appointed CEO, Stephen Brady, emphasizes the significant opportunities in ophthalmological indications.
Company Information
Company
Claris Biotherapeutics
Location
299 PAVONIA AVENUE 3-8
Jersey City, New Jersey, United States
About
Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars. The formulation creates a recombinant hepatocyte growth factor which accelerates the healing process, providing healthcare providers noninvasive therapeutic treatment.
Jersey CityBiotechnology